HIV Drug Resistance among Pre-treatment Cases in Thailand: Four Rounds of Surveys during 2006-2013
DOI:
https://doi.org/10.59096/osir.v11i1.263071Keywords:
antiretroviral therapy, HIV, resistance, pre-treatment, ThailandAbstract
In Thailand, antiretroviral therapy (ART) was initiated to treat human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) cases using the empirical regimen with no prior genotypic test to determine drug resistance. In order to assess prevalence rate of HIV drug resistance (HIVDR) among pre-treatment cases, four rounds of survey were carried out in ART clinics, including six, eight, 33 and four ART clinics in each round during 2006-2013. For which, HIVDR testing results were available in 310, 350, 797, and 413 cases in four rounds. It was revealed that HIVDR rates among naive cases were 2.0%, 2.8%, 4.0% and 4.8%, while in experienced cases, the rates were 0, 3.3%, 11.4% and 13.9%. The rates among all cases were 1.9%, 2.9%, 4.4% and 5.6%. Resistant drugs with the highest rates among all cases in the survey round 4 were nevirapine (3.6%) and efavirenz (3.1%). The results indicated the need to continue surveillance for pre-treatment HIVDR, and posed challenges to implement activities for protecting efficacy and prolong the use of empirical first-line regimen. A strategy to apply genotyping test, in a cost-effective approach, should be considered to prepare for situation when HIVDR increases beyond a critical level.
References
Chasombat S, Lertpiriyasuwat C, Thanprasertsuk S, Suebsaeng L, Lo YR. The national access to antiretroviral program for PHA (NAPHA) in Thailand. Southeast Asian J Trop Med Public Health. 2006;37:704-15.
National AIDS Committee. Thailand AIDS response progress report. 2015 [cited 2017 April 23]. .
National Center for System Development of Antiretroviral Treatment for People with HIV and AIDS, Thailand. National guidelines on HIV/AIDS diagnoses and treatment: Thailand, 2010. Nonthaburi: National Center for System Development of Antiretroviral Treatment for People with HIV and AIDS, Thailand; 2010 Sep. Thai.
Thailand. Bureau of AIDS, TB and STIs. Department of Disease Control. Ministry of Public Health. Thailand national guidelines on HIV/AIDS treatment and prevention 2014. Nonthaburi: Bureau of AIDS, TB and STIs; 2014 Sep. Thai.
Saeng-aroon S, Tsuchiya N, Auwanit W, Ayuthaya PI, Pathipvanich P, Sawanpanyalert P, et al. Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: follow-up study from Lampang cohort. Antiviral Res. 2010 Jul;87(1):22-9. Epub 2010 Apr 9.
Saeng-Aroon S, Wichukchinda N, Myint L, Pathipvanich P, Ariyoshi K, Rojanawiwat A, et al. Study of antiretroviral drug-resistant HIV-1 genotypes in northern Thailand: role of mutagenically separated polymerase chain reaction as a tool for monitoring zidovudine-resistant HIV-1 in resource-limited settings. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1051-6.
Stanford University. HIV drug resistance database [cited 2014 June 23]. <https://hivdb.stanford.edu/>
Sukasem C, Churdboonchart V, Chasombat S, Kohreanudom S, Watitpun C, Pasomsub E, et al. Surveillance of genotypic resistance mutations in chronic HIV-1 treated individuals after completion of the National Access to Antiretroviral Program in Thailand. Infection. 2007 Apr;35(2):81-8.
Blower S, Ma L, Farmer P, Koenig S. Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance. Curr Drug Targets Infect Disord. 2003;3(4):345-53.
Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization’s global strategy for prevention and assessment of HIV drug resistance. Antiviral Therapy. 2008; 13(Suppl 2):1-13.
World Health Organization. Consolidated strategic information guidelines for HIV in the health sector. Geneva: World Health Organization; 2015 May [cited 2017 April 23].
Kiertiburanakul S, Pinsai S, Chantratita W, Pasomsub E, Leechawengwongs M, Thipmontree W, et al. Prevalence of primary HIV drug resistance in Thailand detected by short reverse transcriptase genotypic resistance assay. PLoS One. 2016 Feb 1;11(2):e0147945. eCollection 2016.
Sungkanuparph S, Sukasem C, Kiertiburanakul S, Pasomsub E, Chantratita W. Emergence of HIV-1 drug resistance mutations among antiretroviral-naïve HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand. J Int AIDS Soc. 2012 Mar 12;15(1):12.
Manosuthi W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. HIV-1 drug resistance-associated mutations among antiretroviral-naive Thai patients with chronic HIV-1 infection. J Med Virol. 2013 Feb;85(2):194-9. Epub 2012 Nov 14.
Mankhatitham W, Lueangniyomkul A, Manosuthi W. Prevalence of primary HIV-1 drug resistance among patients with HIV-1 infection/AIDS in Bamrasnaradura Infectious Disease Institute. Disease Control Journal. 2013;39(1):43-50. Thai.
Apisarnthanarak A, Jirayasethpong T, Sa-nguansilp C, Thongprapai H, Kittihanukul C, et al. Antiretroviral drug resistance among antiretroviral-naïve persons with recent HIV infection in Thailand. HIV Med. 2008 May;9(5):322-5.
Pham QD, Do NT, Le YN, Nguyen TV, Nguyen DB, Huynh TK, et al. Pretreatment HIV-1 drug resistance to first-line drugs: results from a baseline assessment of a large cohort initiating ART in Vietnam, 2009-10. J Antimicrob Chemother. 2015 Mar;70(3):941-7. Epub 2014 Nov 27.
Mungati M, Mhangara M, Gonese E, Mugurungi O, Dzangare J, Ngwende S, et al. Pre-treatment drug resistance among patients initiating antiretroviral therapy (ART) in Zimbabwe: 2008-2010. BMC Res Notes. 2016 Jun 10;9:302.
Steegen K, Carmona S, Bronze M, Papathanasopoulos MA, van Zyl G, Goedhals D, et al. Moderate levels of pre-treatment HIV-1 antiretroviral drug resistance detected in the first South African national survey. PLoS One. 2016 Dec 1;11(12):e0166305. eCollection 2016.
AvilaRíos S, GarcíaMorales C, TapiaTrejo D, Meza RI, Nuñez SM, Parham L, et al. HIV drug resistance surveillance in Honduras after a decade of widespread antiretroviral therapy. PLoS One. 2015 Nov 11;10(11):e0142604. doi: 10.1371/journal.pone.0142604. eCollection 2015.
AvilaRíos S, GarcíaMorales C, MatíasFlorentino M, TapiaTrejo D, HernándezÁlvarez BF, MoreiraLópez SE, et al. HIV drug resistance in antiretroviral treatment-naïve individuals in the largest public hospital in Nicaragua, 2011-2015. PLoS One. 2016 Oct 13;11(10):e0164156. eCollection 2016.
Ávila-Ríos S, García-Morales C, Matías-Florentino M, Romero-Mora KA, Tapia-Trejo D, Quiroz-Morales VS, et al. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey. Lancet HIV. 2016 Dec;3(12):e579-e591. Epub 2016 Sep 14.
World Health Organization. HIV drug resistance surveillance guidance – 2015 update. Geneva: World Health Organization; 2016 [cited 2017 April 23].
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Outbreak, Surveillance, Investigation & Response (OSIR) Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
